Organization: Working Ventures Canadian Fund Inc

Cytochroma Inc raises additional $21 million in VC

Privately held Cytochroma Inc, Markham ON, has received $21 million in venture capital financing to expand the development of potential products for vitamin D deficiency and other diseases related to chronic kidney disease. The latest funding brings the total raised since 2001 to $58 million and follows last year’s acquisition of Madison WI-based Proventiv Therapeutics…

Cytochroma secures $12-million private financing

Kingston ON-based Cytochroma Inc has closed a $12-million private equity financing to advance its R&D of therapeutics based on cytochrome P450-based metabolism. The Business Development Bank of Canada’s Venture Capital Division is the lead investor, with participation from Novo A/S (Denmark), GeneChem Technologies Venture Fund LP, Canadian Medical Discoveries Fund and Working Ventures Canadian Fund…